|MDACC Study No:||2013-0706 (clinicaltrials.gov NCT No: NCT02096042)|
|Title:||A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In CD30-Positive Relapsed/Refractory Acute Myeloid Leukemia|
|Principal Investigator:||Nitin Jain|
|Treatment Agent:||5-Azacytidine; Brentuximab Vedotin|
|Study Description:||This clinical research study is made up of 3 phases: a Pilot Phase, Phase 1, |
and Phase 2.
The goal of the Pilot Phase is to learn how safe it is to give the study drug
brentuximab vedotin to patients with AML. The goal of Phase 1 is to learn more
about the safety of the combination of brentuximab vedotin with azacytidine.
The goal of Phase 2 is to learn if the combination of brentuximab vedotin and
azacytidine can help to control AML.